Login to Your Account



$525M Gets Emtriva Interest From Emory For Gilead, Royalty Pharma

By Karen Pihl-Carey


Wednesday, July 20, 2005
Gilead Sciences Inc. and Royalty Pharma bought out Emory University's royalty interest in emtricitabine - or Emtriva - for $525 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription